NCT06725693

Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Tianjin Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

To evaluate the potential usefulness of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.

Detailed description

Subjects with various GLP1-R-related disease patients underwent 68Ga/18F-Exendin 4 PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga/18F-Exendin 4 PET/CT were calculated.

Conditions

• GLP1-R-related Disease
• Tumor
• Insulinoma
• Positron Emission Tomography

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	18F/68Ga-Exendin 4	Each subject receive a single intravenous injection of 68Ga/18F-Exendin 4, and undergo PET/CT imaging within the specificed time.

Timeline

• Start date: 2019-02-01
• Primary completion: 2027-11-01
• Completion: 2027-11-01
• First posted: 2024-12-10
• Last updated: 2025-02-11

Locations

1 site across 1 country: China